J M V Pons1, C Tebé, N Paladio, A Garcia-Altes, I Danés, A Valls-I-Soler. 1. Agència d'Avaluació de Tecnologia i Recerca Mèdiques (Catalan Agency for Health Technology Assessment and Research), Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. joan.ponsr@gencat.cat
Abstract
AIM: To review respiratory syncytial virus (RSV), passive immunoprophylaxis (PI) trials and meta-analysis (MA). METHODS: A literature review. RESULTS: Two MA of PI were found. Overall 3927 patients were randomized. PI reduces RSV hospitalization in patients with bronchopulmonary dysplasia (RR 0.58; 95% CI 0.41, 0.82) and with acyanotic congenital heart disease (RR 0.29; 95% CI 0.14, 0.62). In patients with cyanotic heart disease or premature infants without bronchopulmonary dysplasia, results are inconclusive. Passive immunoprophylaxis has a null effect in mechanical ventilation and death. CONCLUSION: Passive immunoprophylaxis reduces RSV hospitalization in a subset of patients. However, it has no effect in harder endpoints of RSV disease severity.
AIM: To review respiratory syncytial virus (RSV), passive immunoprophylaxis (PI) trials and meta-analysis (MA). METHODS: A literature review. RESULTS: Two MA of PI were found. Overall 3927 patients were randomized. PI reduces RSV hospitalization in patients with bronchopulmonary dysplasia (RR 0.58; 95% CI 0.41, 0.82) and with acyanotic congenital heart disease (RR 0.29; 95% CI 0.14, 0.62). In patients with cyanotic heart disease or premature infants without bronchopulmonary dysplasia, results are inconclusive. Passive immunoprophylaxis has a null effect in mechanical ventilation and death. CONCLUSION: Passive immunoprophylaxis reduces RSV hospitalization in a subset of patients. However, it has no effect in harder endpoints of RSV disease severity.
Authors: Javier Díez-Domingo; Eduardo G Pérez-Yarza; José A Melero; Manuel Sánchez-Luna; María Dolores Aguilar; Antonio Javier Blasco; Noelia Alfaro; Pablo Lázaro Journal: BMC Infect Dis Date: 2014-10-30 Impact factor: 3.090